Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell ...(ons as an instructor in medicine at Har...),Health

Date:5/18/2009

ons as an instructor in medicine at Harvard Medical School and assistant in medicine at Massachusetts General Hospital. His postdoctoral training includes a fellowship in hematology and oncology at Dana-Farber/Partners and an internship and residency in Internal Medicine at Massachusetts General Hospital. Dr. Multani received his M.S. in clinical epidemiology from Harvard School of Public Health, his M.D. from Harvard Medical School, and he graduated summa cum laude from Yale University with a B.S. in chemistry and biology.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem (iPS) cell technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic stem cell support. In addition, Fate Therapeutics and Stemgent have formed an alliance - Catalyst - a collaborative program to provide its partners with first access to the most advanced induced pluripotent stem (iPS) cell technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.

Fate Therapeutics along with Stemgent, Genzyme, Burrill & Company and WIRED Magazine, will be featured in a panel presentation entitled "Mastering Your (Cell) Fate: Stem Cells, iPSCs and t
'/>"/>

SOURCE Fate Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
2. Nile Therapeutics Reports 2009 First Quarter Financial Results
3. Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
4. Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
5. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
6. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
7. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $20 Million of Common Stock and Warrants
9. Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
10. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
11. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA